COMMUNIQUÉS West-GlobeNewswire

CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
25/03/2025
‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., March [...]
Aurora Spine Announces FDA 510(k) Clearance for the AERO™ Facet Fusion System
25/03/2025
CARLSBAD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, [...]
Sanara MedTech Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (Unaudited)
25/03/2025
Q4 Net Revenue Increased 49% Year-Over-Year; 2024 Net Revenue Increased 33% Year-Over-Year FORT WORTH, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: [...]
NMD Pharma presents preclinical data highlighting increased innervation of skeletal muscle with ClC-1 ion channel inhibition treatment in neuromuscular disease model
25/03/2025
Company presented clinical and preclinical data at the MDA Conference last week in Dallas, Texas Oral presentation included data from MuSK-MG rat model depicting increases in muscle function and improvements in the [...]
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
25/03/2025
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company’s industry-leading pipeline of active immunotherapies for [...]
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
25/03/2025
Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan Tumor response models for novel compounds represent true drug [...]
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint
25/03/2025
Demonstrated substantial and statistically significant improvement in ADHD symptoms as measured by the AISRS total score compared to placebo (p=0.039, primary endpoint, 150 mg solriamfetol) Statistically significant [...]
Teleflex Announces Updated Clinical Study Data Presented at the European Association of Urology (EAU) Congress
25/03/2025
WAYNE, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that new findings from the CLEAR study were presented at the 40th [...]
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
25/03/2025
In February 2025, BiomX announced a series of financings with total gross proceeds of approximately $12 million to support completion of Phase 2b study of BX004; topline results anticipated in Q1 2026 Topline Phase 2 [...]
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
25/03/2025
Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis Continued demonstration of favorable tolerability profile generally [...]
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
25/03/2025
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026 4WARD trial protocol refined, increasing [...]
Alviona who wants to be my Alviona Avis partner Weight Loss Results
25/03/2025
ALMERE, Netherlands, March 25, 2025 (GLOBE NEWSWIRE) -- The foundation of weight reduction therapy, which was discovered a century ago, is the utilization of the body's innate mechanism for energy production. Due to its [...]
Philips demonstrates innovation power, topping European Patent Office Medtech filings in 2024
25/03/2025
March 25, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that in 2024 it was the leading applicant in the field of medical technology at the [...]
Allegro’s injectable osteoarthritis treatment generates positive safety results in preclinical studies
25/03/2025
Microparticle hydrogel shows clean systemic toxicity profile over 4 weeks and 13 weeks Treatment designed to restore shock-absorbing capacities of joints in osteoarthritis Allegro plans to start pivotal clinical trials [...]
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program
25/03/2025
Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals, Inc. (“Eton”) by [...]
CROSSJECT fait le point sur sa collaboration avec ETON PHARMACEUTICALS, Inc. et sur le programme ZENEO® Hydrocortisone dans le domaine de l'insuffisance surrénale
25/03/2025
Communiqué de presse CROSSJECT fait le point sur sa collaboration avec ETON PHARMACEUTICALS, Inc. et sur le programme ZENEO® Hydrocortisone dans le domaine de l'insuffisance surrénale CROSSJECT a renforcé sa [...]
Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
25/03/2025
- Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties on future sales - [...]
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
25/03/2025
Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients to be presented [...]
Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
25/03/2025
Saint-Herblain (France), March 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 24, 2025, of its 2024 Universal Registration Document (URD) [...]

Pages